+

PE20060465A1 - Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa - Google Patents

Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa

Info

Publication number
PE20060465A1
PE20060465A1 PE2005000582A PE2005000582A PE20060465A1 PE 20060465 A1 PE20060465 A1 PE 20060465A1 PE 2005000582 A PE2005000582 A PE 2005000582A PE 2005000582 A PE2005000582 A PE 2005000582A PE 20060465 A1 PE20060465 A1 PE 20060465A1
Authority
PE
Peru
Prior art keywords
policosanol
coa
hmg
compositions containing
reductase inhibitor
Prior art date
Application number
PE2005000582A
Other languages
English (en)
Inventor
Roger Berlin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20060465A1 publication Critical patent/PE20060465A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE POLICOSANOL Y UN INHIBIDOR DE LA ENZIMA HMG-COA REDUCTASA DE METILGLUTARIL. DICHO POLICOSANOL COMPRENDE UNA MEZCLA DE ALCOHOLES ALIFATICOS PRIMARIOS DE CADENA RECTA CON UN LARGO DE 20 A 36 ATOMOS DE CARBONO, ENTRE LOS CUALES SE ENCUENTRAN 1-EICOSANOL, 1-DOCOSANOL, 1-TETRACOSANOL, ENTRE OTROS. EL INHIBIDOR DE HMG-COA ES UNA ESTATINA TAL COMO LOVASTATIN, ROSUVASTATIN, PRAVASTATIN, ENTRE OTRAS. EL POLICOSANOL Y LA ESTATINA SE ENCUENTRAN EN UNA PROPORCION DE ENTRE 100:1 A 0,01:1 POR PESO. TAMBIEN ESTA REFERIDA A UNA PREPARACION TRANSDERMICA CON LIBERACION SOSTENIDA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES HIPERCOLESTEROLEMICAS, COLESTEROL TOTAL, COLESTEROL LDL, ENFERMEDAD CARDIACA CORONARIA, INFLAMACION, ENTRE OTRAS
PE2005000582A 2004-05-25 2005-05-25 Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa PE20060465A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/853,578 US20050267197A1 (en) 2004-05-25 2004-05-25 Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses

Publications (1)

Publication Number Publication Date
PE20060465A1 true PE20060465A1 (es) 2006-06-12

Family

ID=35426221

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000582A PE20060465A1 (es) 2004-05-25 2005-05-25 Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa

Country Status (4)

Country Link
US (1) US20050267197A1 (es)
PE (1) PE20060465A1 (es)
TW (1) TW200605865A (es)
WO (1) WO2005115381A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) * 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050282883A1 (en) * 2004-04-29 2005-12-22 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
JP2008509154A (ja) * 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
AU2005271407A1 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
ES2369787T3 (es) * 2005-02-17 2011-12-07 Chiesi Farmaceutici S.P.A. Combinaciones terapéuticas de manidipina y simvastatina.
US20070015779A1 (en) * 2005-04-29 2007-01-18 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
CN101431982A (zh) 2006-04-26 2009-05-13 罗斯蒙特制药有限公司 口服液体组合物
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100178341A1 (en) * 2008-06-11 2010-07-15 Ranbaxy Laboratories Limited BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US8557236B2 (en) * 2010-02-09 2013-10-15 Vascure Natural LLC Cardiovascular support supplement and compositions and methods thereof
CA2810243C (en) 2010-09-15 2021-04-20 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US20130295173A1 (en) 2012-05-07 2013-11-07 Omthera Pharmaceuticals, Inc. Compositions of statins and omega-3 fatty acids
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN114903862B (zh) * 2022-06-15 2023-08-22 湖北中古生物制药有限公司 一种多廿烷醇阿托伐他汀钙复方制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031376A (en) * 1956-10-11 1962-04-24 Levin Compositions comprising octacosanol, triacontanol, tetracosanol, or hexacosanol, andmethods employing same
US4623667A (en) * 1985-06-28 1986-11-18 Richardson-Vicks Inc. Topical treatment of skin inflammatory disorders
US4793991A (en) * 1986-01-31 1988-12-27 Slimak Karen M Hypoallergenic cosmetics, lip balms and lip sticks
US5166156A (en) * 1989-12-20 1992-11-24 Adir Et Compagnie Naphthyl piperazines useful as 5-HT1A receptor ligands
CU22229A1 (es) * 1992-09-29 1996-01-31 Dalmer Lab Sa Policosanol, una mezcla de alcoholes alifaticos primarios superiores para hipergregabilidad plaquetaria, los accidentes isquemicos, trombosis e incluso efectividad contra ulceras gastricas quimicamente inducidas y su proceso de obtencion de la caña de azucar. el tratamiento de complicaciones ateroscleroticas tales como la
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6596776B2 (en) * 1999-06-21 2003-07-22 Hauser, Inc. High molecular weight primary aliphatic alcohols obtained from natural products and uses thereof
ES2296711T3 (es) * 2000-08-03 2008-05-01 Harting, Thomas Francis Composiciones farmaceuticas y alimenticias que contienen alcoholes de madera o esteroles de madera utiles para rebajar el colesterol del suero.
WO2003020260A1 (en) * 2001-08-31 2003-03-13 Metaproteomics, Llc Arginine compositions for coordinate modification of multiple cardiovascular risk factors
JP4533134B2 (ja) * 2002-06-10 2010-09-01 エラン ファーマ インターナショナル,リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
US6890941B1 (en) * 2003-12-03 2005-05-10 Procaps S.A. Compositions containing HMG Co-A reductase inhibitors and policosanol

Also Published As

Publication number Publication date
WO2005115381A3 (en) 2007-05-24
US20050267197A1 (en) 2005-12-01
WO2005115381A2 (en) 2005-12-08
TW200605865A (en) 2006-02-16

Similar Documents

Publication Publication Date Title
PE20060465A1 (es) Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa
ES2500063T3 (es) Composición para prevenir la aparición de acontecimiento cardiovascular en paciente con riesgo múltiple
ECSP066529A (es) Derivados de tetrazol y métodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
AR018777A1 (es) Composicion farmaceutica que contiene una combinacion de una estatina y aspirina y metodo.
PE20050128A1 (es) Formulacion farmaceutica
ES2721148T3 (es) Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso
ECSP10010433A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
MA32711B1 (fr) Pyrrolidine-2-carboxamides substitues
PE20080523A1 (es) Composiciones farmaceuticas topicas que comprenden un modificador de respuesta inmune
ECSP078053A (es) Nuevos derivados de 2-azetidinona útiles en el tratamiento de condiciones de hiperlipidemia
SV2009003305A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
MA29909B1 (fr) Derives de pyridazine
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
EA201290596A1 (ru) Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице
PE20120476A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
CR9954A (es) Derivados de pirazina
CR10452A (es) Derivados de terfenilo para el tratamiento de enfermedad de alzheimer
AR076263A1 (es) Composiciones y metodos para tratar cancer. uso.
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
PE20000017A1 (es) Combinaciones de estatina-eter carboxialquilico
GT199900081A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos.
BR112013028920A2 (pt) álcoois terpênicos para uso em composições fragrantes e produtos perfumados
UY30675A1 (es) Metodos para el tratamiento de la depresion
PE20070603A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE ESCUALENO SINTASA Y UN INHIBIDOR DE 3-HIDROXI-3-METILGLUTARIL-CoA-REDUCTASA (HMG-CoA)

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载